Continuing LBPD is a viable treatment option for select patients with ALK-positive NSCLC who progressed on lorlatinib. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2021.12.011
Authors: Sai-Hong I.Ou, Benjamin J.Solomon, Alice T.Shaw, Shirish M.Gadgeel, BenjaminBesse, Ross A.Soo, Antonello Abbattista, Francesca Toffalorio, Robin Wiltshire, Alessandra Bearz
This study assessed the prevalence of anaplastic lymphoma kinase (ALK) rearrangements in US oncology practices. The cohort included 19,895 eligible patients with a mean age 68.5 years, majority ever-smokers (85.5%) and from community centers (92.2%). The overall ALK rearrangement prevalence was 2.6%. Positivity rate varied by histology and smoking status; it was the highest among non-smoking patients with non-squamous histology (9.3%). Differences in ALK status also varied by age and race, with young patients (18–39 years) having a higher prevalence (21.6%) vs. older patients (age ≥55 = 2.2%); Asian patients had a prevalence of 6.3%. Patients that were positive for other mutations or rearrangements had a lower ALK positivity rate (0.5%) and patients positive for PD-L1 had a rate of 3.0%. Conclusion: The likelihood of finding an ALK translocation was highest in younger patients and nonsmokers; however, age and smoking history were not discriminative enough to exclude testing based on cl..... READ ARTICLE
Oncotarget DOI:10.18632/oncotarget.28114
Authors: Allen T. Craig, Xiao Y., Yang B., Croix D., Abraham A., Redpath S., Engstrom-Melynk J., Shah R., Madala J., Bernicker E. H.